Show simple item record

dc.contributor.authorCapeloa, Tania
dc.contributor.authorKrzystyniak, Joanna
dc.contributor.authorRodriguez, Amanda Canas
dc.contributor.authorPayen, Valéry L
dc.contributor.authorZampieri, Luca X
dc.contributor.authorPranzini, Erica
dc.contributor.authorDerouane, Françoise
dc.contributor.authorVazeille, Thibaut
dc.contributor.authorBouzin, Caroline
dc.contributor.authorDuhoux, François P
dc.contributor.authorMurphy, Mike
dc.contributor.authorPorporato, Paolo E
dc.contributor.authorSonveaux, Pierre
dc.description.abstractIn oncology, the occurrence of distant metastases often marks the transition from curative to palliative care. Such outcome is highly predictable for breast cancer patients, even if tumors are detected early, and there is no specific treatment to prevent metastasis. Previous observations indicated that cancer cell mitochondria are bioenergetic sensors of the tumor microenvironment that produce superoxide to promote evasion. Here, we tested whether mitochondria-targeted antioxidant MitoQ is capable to prevent metastasis in the MDA-MB-231 model of triple-negative human breast cancer in mice and in the MMTV-PyMT model of spontaneously metastatic mouse breast cancer. At clinically relevant doses, we report that MitoQ not only prevented metastatic take and dissemination, but also local recurrence after surgery. We further provide in vitro evidence that MitoQ does not interfere with conventional chemotherapies used to treat breast cancer patients. Since MitoQ already successfully passed Phase I safety clinical trials, our preclinical data collectively provide a strong incentive to test this drug for the prevention of cancer dissemination and relapse in clinical trials with breast cancer patients.
dc.publisherMDPI AG
dc.rightsAttribution 4.0 International
dc.sourcenlmid: 101526829
dc.sourceessn: 2072-6694
dc.subjectBreast cancer
dc.subjectTranslational Research
dc.subjectMitochondria-targeted Antioxidant
dc.subjectMitochondrial Superoxide
dc.subjectMetastasis Prevention
dc.subjectCancer Relapse
dc.titleMitoQ Prevents Human Breast Cancer Recurrence and Lung Metastasis in Mice.
prism.publicationNameCancers (Basel)
dc.contributor.orcidCapeloa, Tania [0000-0001-8034-5524]
dc.contributor.orcidZampieri, Luca X [0000-0002-9286-7693]
dc.contributor.orcidPranzini, Erica [0000-0002-1668-2777]
dc.contributor.orcidDerouane, Françoise [0000-0002-0199-1366]
dc.contributor.orcidBouzin, Caroline [0000-0003-0694-1947]
dc.contributor.orcidDuhoux, François P [0000-0002-5429-7888]
dc.contributor.orcidMurphy, Mike [0000-0003-1115-9618]
dc.contributor.orcidPorporato, Paolo E [0000-0001-8519-1552]
dc.contributor.orcidSonveaux, Pierre [0000-0001-6484-8834]
pubs.funder-project-idEuropean Union (European Union's Horizon 2020 research innovation program under the Marie Skłodow-ska-Curie grant agreement No 722605 TRANSMIT, FP7/2007-2013 ERC Independent Researcher Starting Grant 243188 TUMETABO, European Union’s Horizon 2020 research innovation program under the Marie Skłodow-ska-Curie grant agreement No 722605 TRANSMIT)
pubs.funder-project-idFondation Belge contre le Cancer (Fundamental Research Grants #F86 and #FAF-F/2018/1282, N/A, Grants 7.4508.14 and 7.4529.17, grants FRSM 3.4567.10, FRFC 2.5025.12, CDR J.0135.18, U.G002.19)
pubs.funder-project-idTélévie (Grants 7.4508.14 and 7.4529.17)
pubs.funder-project-idBelgian Science Policy Office (Interuniversity Attraction Pole (IAP) grant #UP7-03)
pubs.funder-project-idFund for Scientific Research (grants FRSM 3.4567.10, FRFC 2.5025.12, CDR J.0135.18, U.G002.19)
pubs.funder-project-idCommunauté Française de Belgique (ARC 09/14-020 and ARC 14/19-058)
pubs.funder-project-idUCLouvain Fonds Spéciaux de la Recherche (FSR) (N/A)
pubs.funder-project-idLouvain Foundation (N/A)
pubs.funder-project-idFonds Joseph Maisin (N/A)

Files in this item


This item appears in the following Collection(s)

Show simple item record

Attribution 4.0 International
Except where otherwise noted, this item's licence is described as Attribution 4.0 International